In the vascular business, the company is developing a next-generation Drug Eluting Stent, XIENCE Xpedition, which is expected to launch in Europe this year and in the U.S. in 2013.

FORBES: Abbott Labs Snapshot As AbbVie Begins Trading

The new Abbott also sells medical devices such as artery-clearing drug-eluting Xience stent or its absorbable stent known as Absorb and diagnostic tests used in laboratories and hospitals such as its Architect platform.

FORBES: Move up http://i.forbesimg.com t Move down

Data presented at the EuroPCR 2012 congress this week demonstrated that in more than 10, 000 real-world patients treated with XIENCE PRIME and XIENCE V, no cases of stent thrombosis were reported in patients who discontinued DAPT after three months post-stent implantation.

FORBES: Xience Stents Gain European Nod For Three-Month Dual Antiplatelet Therapy

Moderate growth is expected from vascular and diagnostics division (excluding to certain royalty and supply arrangement revenues and currency impact), after the company launched various products including its next-generation Drug Eluting Stent XIENCE Xpedition and XIENCE PRIME in different parts of the world.

FORBES: Abbott Earnings Preview: What We Are Watching